Alzheimer's Disease

Lipoic acid: a novel therapeutic approach for multiple sclerosis and other chronic inflammatory dise
The naturally occurring antioxidant lipoic acid (LA) was first described as an essential cofactor for the conversion of pyruvate to Acetyl-CoA, a critical step in respiration.
VAMC RD-8, 3710
Portland, OR 97239
USA
Emerging amyloid beta (Ab) peptide modulators for the treatment of Alzheimer's disease (AD).
BACKGROUND: According to the 'amyloid cascade hypothesis' of Alzheimer's disease (AD), abnormal processing of beta-amyloid precursor protein (betaAPP) into toxic amyloid beta (Abeta)-peptides is central to the etiopathology of this uniquely human brain disorder.
2020 Gravier Street, Suite 8B8
New Orleans, LA 70112-2272
USA
No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized c
BACKGROUND: The objective of this study was to determine whether treatment with the nonselective nonsteroidal anti-inflammatory drug (NSAID) indomethacin slows cognitive decline in patients with Alzheimer's disease (AD).

Nijmegen, The Netherlands
The Netherlands
[Antidementia drugs - response or non-response?]
Due to the heterogeneous course of illness in individual cases, efficacy or "treatment-response" can not be measured in single patients; therefore a clinical distinction between response and non-response is not meaningful. Constructs which are valid for research projects become misnomers in clinical practice.
Klinikum rechts der Isar, Ismaningerstraße 22
München, Germany 81675
Germany
Losing one's memory in early Alzheimer's disease
A Heideggerian hermeneutical phenomenological research method was used to investigate the experience of memory loss in twelve individuals with early Alzheimer's disease or mild cognitive impairment.

Newfoundland, Canada
Canada